Sign In

Robert Habib

CEO at MiNA Therapeutics

Robert Habib is the CEO of MiNA Therapeutics, a biotechnology company pioneering a new class of RNA medicines called small activating RNAs (saRNAs).12 He joined MiNA as the founding CEO in 2013, overseeing its growth into a clinical-stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners.23

Prior to MiNA, Habib held roles in private equity and investment banking, including positions at Deutsche Bank and Stirling Square Capital Partners.3 He has a BSc in Economics and Politics from the University of Bristol and an MBA from Columbia Business School.23

Under Habib's leadership, MiNA Therapeutics has:

  • Established itself as a leader in saRNA therapeutics
  • Attracted over $100 million in funding
  • Advanced its technology through clinical trials
  • Formed partnerships with major pharmaceutical companies123

Habib's interest in healthcare stems from his family background, with both his parents and sister being doctors.4 He views his role in biotech as a calling, committed to discovering new medicines that can make a significant impact on patients' lives.14

Highlights

Sep 23 · lifescienceorg.com
Meet the LifeScience ORG CEO
Interview with Robert Habib, MBA
Interview with Robert Habib, MBA

Related Questions

What inspired Robert Habib to join MiNA Therapeutics?
How has Robert Habib's background in private equity and investment banking influenced his leadership at MiNA Therapeutics?
What are some of the key milestones achieved under Robert Habib's leadership at MiNA Therapeutics?
How does Robert Habib's vision for RNA activation therapeutics differ from other approaches in the field?
What challenges has Robert Habib faced in developing MiNA Therapeutics, and how has he overcome them?
Robert Habib
Robert Habib, photo 1
Robert Habib, photo 2
Add to my network

Location

Greater London, England, United Kingdom